Emergent BioSolutions (NYSE:EBS) Raised to Buy at StockNews.com

Emergent BioSolutions (NYSE:EBS - Get Free Report) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Monday.

Several other equities research analysts have also weighed in on EBS. Benchmark lifted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Emergent BioSolutions in a research report on Tuesday, January 21st.

Emergent BioSolutions Stock Down 1.3 %

Shares of NYSE EBS traded down $0.10 during mid-day trading on Monday, hitting $7.74. 1,293,494 shares of the stock traded hands, compared to its average volume of 1,032,864. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a 52 week low of $1.82 and a 52 week high of $15.10. The company has a market cap of $419.41 million, a price-to-earnings ratio of -1.89 and a beta of 1.62. The stock has a fifty day moving average price of $9.67 and a 200-day moving average price of $9.09.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EBS. Covestor Ltd increased its position in Emergent BioSolutions by 5,458.5% during the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Emergent BioSolutions during the fourth quarter valued at $63,000. E Fund Management Co. Ltd. purchased a new stake in Emergent BioSolutions during the fourth quarter valued at $98,000. EP Wealth Advisors LLC purchased a new stake in Emergent BioSolutions during the fourth quarter valued at $110,000. Finally, Stifel Financial Corp purchased a new stake in Emergent BioSolutions during the third quarter valued at $96,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.